Last reviewed · How we verify
NCT03092882
Digital Self-Management Program for Medicare Advantage Members With Type 2 Diabetes- Impact on A1c
NA trial testing Diabetes Self-Management Program in Diabetes Mellitus, Type 2 in 607 participants. Completed in 7 February 2018.
7 February 2018
Quick facts
| Lead sponsor | Evidation Health |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | health services research |
| Enrollment | 607 |
| Start date | 3 March 2017 |
| Primary completion | 7 February 2018 |
| Estimated completion | 7 February 2018 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Diabetes Self-Management Program
Conditions studied
- Diabetes Mellitus, Type 2 — all drugs for Diabetes Mellitus, Type 2 →
Sponsor
Evidation Health
Who can join
18 and older, any sex, with Diabetes Mellitus, Type 2. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The Digital Self-Management Program for Medicare Advantage Members with Type 2 Diabetes - Impact on A1c trial is a 26-week long, prospective, intent-to-treat, 2-arm randomized controlled trial that aims to evaluate the impact of the Digital Self-Management Program on A1c levels for individuals with uncontrolled Type 2 diabetes.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03092882
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Diabetes Self-Management Program
Trials testing the same drug.
- NCT01642394 — Impact of Self-care Education Program in Patients With Type 2 Diabetes in Primary Care in the Basque Country · NA · completed
Other recruiting trials for Diabetes Mellitus, Type 2
Currently open trials in the same condition.
- NCT07415954 — A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 · Phase 2 · recruiting
- NCT07532863 — A Real-world Study to Investigate Cardiovascular Risk Profile Among Newly Diagnosed Type 2 Diabetes Mellitus (T2DM) Part · recruiting
- NCT07336329 — Continuous Glucose Monitoring in Non-Insulin Treated Type 2 Diabetes: Continuous vs. Periodic Use · NA · recruiting
- NCT07242469 — A Clinical Trial of MK-1403 in Participants With Type 2 Diabetes Mellitus (MK-1403-006) · Phase 1 · recruiting
- NCT07444203 — Transformative Research in Diabetic Nephropathy 2.0 · recruiting
Other Evidation Health trials
Trials by the same sponsor.
- NCT06229444 — Predict + Protect Study: Exploring the Effectiveness of a Predictive Health Education Intervention on the Adoption of Pr · NA · completed
- NCT06207929 — Wearable Assisted Viral Evidence (WAVE) Study A Decentralized, Prospective Study Exploring the Relationship Between Pass · completed
- NCT04623138 — A Virtual Prospective Study Exploring Activity Trackers and COVID-19 Infections · completed
- NCT04584645 — A Digital Flu Intervention for People With Cardiovascular Conditions · NA · completed
- NCT04245800 — Home Testing of Respiratory Illness · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03092882 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Evidation Health
- Last refreshed: 25 June 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03092882.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing